Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

Figures & data

Table 1 Patient baseline demographics and clinical characteristics (randomized population)

Characteristic	Japanese, N=338	Caucasian, N=1,275
Age, years	59.3±10.2	55.8±10.6
Sex
Female, n (%)	106 (31.4)	544 (42.7)
Male, n (%)	232 (69.0)	731 (57.0)
BMI, kg/m^2	24.8±3.2	32.0±5.3
HbA1c, mmol/mol	62.9±9.2	70.1±11.5
FPG, mmol/L	8.8±1.7	10.5±2.6
HOMA-IR	3.3±2.3	7.1±7.0

Note: Data are presented as mean ± standard deviation or as n (%).

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model of assessment for insulin resistance.

Figure 1 Mean change in HbA1c (millimoles per mole) as a function of baseline AGLU, with race subgroup as factor for vildagliptin 50 mg bid treatment.

Abbreviations: bid, twice daily; HbA1c, glycated hemoglobin.

Table 2 Linear regression analyses for change in HbA1c (millimoles per mole) at Week 12 from baseline

Race	n	Intercept	Slope (SEM)	95% confidence interval
Caucasian	1,275	17.17	−0.41 (0.03)	−0.465, −0.357
Japanese	338	15.39	−0.41 (0.03)	−0.468, −0.351

Abbreviations: HbA1c, glycated hemoglobin; SEM, standard error of the mean.